Kazia Therapeutics Limited: KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
SYDNEY, Aug. 5, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new
New York United States Memorial Sloan Kettering Cancer Center New South Wales Jonathan Yang James Garner
Source: finanznachrichten.de